Whitehead Group Contributes SNP--Discovery Technology To Consortium | GenomeWeb

CAMBRIDGE, Mass.--The Whitehead Functional Genomics Consortium, made up of Millennium Pharmaceuticals, Bristol-Myers Squibb, Affymetrix, and the Whitehead Institute for Biomedical Research, announced that it has allowed the SNP Consortium to use its technology for identifying single-nucleotide polymorphisms (SNPs) at no cost. The SNP Consortium, established earlier this year by 10 major pharmaceutical companies and the Wellcome Trust, is funding an effort to create a map of SNPs in the human genome.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.